Mastery of innovative bioproduction techniques
The LFB group has mastered various bioproduction techniques, some of which are particularly innovative.
LFB produces recombinant proteins through cell culture at its Alès site in France (LFB BIOMANUFACTURING), which boasts specific know-how in the field of monoclonal antibodies. LFB BIOMANUFACTURING produces clinical batches of recombinant proteins and monoclonal antibodies.
The LFB has two subsidiaries located in the USA: rEVO Biologics, specialised in the development and marketing of the Group's recombinant antithrombin, and LFB USA, dedicated to research, development, and manufacture of recombinant proteins. These medicinal products are the result of a highly innovative technology that involves the expression of the required protein through DNA recombination in mammalian milk. The protein is then isolated, purified and made safety compliant according to the highest pharmaceutical standards, based on LFB’s cutting edge expertise in these areas.
LFB’s subsidiary CELLforCURE is a key industrial and pharmaceutical player in the emerging field of cell therapy. With a capacity of 5,000 batches per year, CELLforCURE’s industrial facility is the first modular entity of this size in Europe and is able to produce up to eight different cell therapy medicines simultaneously. CELLforCURE operates based on a combined model, as both a CMO (Contract Manufacturing Organisation) offering production services, and a pharmaceutical company that develops, manufactures and markets cell therapy medicinal products.